Subtitle: Market Intelligence, Clinical Progress, and High-Performance Reagents for Purinergic Receptor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for P2RY13 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | P2RY13 Overexpression Lysate / Custom Protein HEK293 Expressed (Native Glycosylation), Sequence Verified, High Purity, Endotoxin Controlled. |
View P2RY13 Products |
| Gene Delivery | P2RY13 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Crucial for GPCR functional conformation. |
View P2RY13 Products |
| Benchmark Ab | Anti-P2RY13 Recombinant Antibody Recombinant positive control for flow cytometry and binding assays. |
View P2RY13 Products |
| Validator | P2RY13 siRNA Set For target knockdown verification and specificity validation. |
View P2RY13 Products |
| Related Target A | P2RY12 Highly homologous ADP receptor. Essential counter-screening target to avoid platelet aggregation off-target effects. |
View P2RY12 Products |
| Related Target B | P2RY1 Co-expressed purinergic receptor. Synergistic target in metabolic and inflammatory pathways. |
View P2RY1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Native Conformation Retention | Lentiviral transduction vectors optimized for high-density surface expression on CHO/HEK293 cells. |
| Subfamily Cross-Reactivity (P2RY12/14) | Validated ortholog and homolog control panels available for high-throughput selectivity screening. |
| Lack of Controls | Sequence-verified biosimilar antibodies and positive control lysates included in the workflow. |
| False Positives | Sequence-specific siRNA pools included for functional gene knockdown validation. |
Live P2RY13 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for P2RY13 therapeutics is intensifying, with major players shifting focus from traditional small molecules to highly selective GPCR modulators. As first-generation therapies for metabolic and inflammatory disorders reach the clinic, the next wave of R&D is targeting P2RY13's role in the tumor microenvironment, bone remodeling, and neuropathic pain pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Antagonist) | Academic Institutions, Biotech Startups | Neuropathic Pain, Asthma, Osteoporosis | Selectivity Assay (Need P2RY12/P2RY13 cell-based screening panels) |
| Monoclonal Antibody | Global Biopharma | Oncology, Chronic Inflammation | Conformation-Specific Binding (Need Lentivirus-driven stable cell lines) |
| RNA Therapeutics | Gene Therapy Pioneers | Metabolic Syndromes | Target Knockdown Verification (Need validated siRNA and qPCR controls) |